RhumbLine Advisers
LYEL icon

RhumbLine Advisers’s Lyell Immunopharma LYEL Stock Holding History

RhumbLine Advisers’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Buy
+15,462
New +$280K ﹤0.01% 3242
2025
Q2 		– Sell
-11,785
Closed -$127K – 4210
2025
Q1 		$127K Sell
11,785
-2,271
-16% -$27.8K ﹤0.01% 3305
2024
Q4 		$180K Buy
14,056
+367
+3% +$7.28K ﹤0.01% 3250
2024
Q3 		$378K Buy
13,689
+652
+5% +$19.2K ﹤0.01% 2893
2024
Q2 		$378K Sell
13,037
-872
-6% -$41.5K ﹤0.01% 2853
2024
Q1 		$620K Buy
13,909
+365
+3% +$15.6K ﹤0.01% 2526
2023
Q4 		$526K Buy
13,544
+103
+0.8% +$3.71K ﹤0.01% 2627
2023
Q3 		$395K Sell
13,441
-304
-2% -$14.4K ﹤0.01% 2750
2023
Q2 		$874K Buy
13,745
+142
+1% +$7.86K ﹤0.01% 2366
2023
Q1 		$642K Buy
13,603
+442
+3% +$23.6K ﹤0.01% 2318
2022
Q4 		$913K Sell
13,161
-225
-2% -$22.4K ﹤0.01% 2173
2022
Q3 		$1.96M Buy
13,386
+901
+7% +$122K ﹤0.01% 1773
2022
Q2 		$1.63M Buy
12,485
+4,916
+65% +$502K ﹤0.01% 1884
2022
Q1 		$764K Buy
7,569
+6,404
+550% +$776K ﹤0.01% 2243
2021
Q4 		$180K Buy
1,165
+321
+38% +$71.6K ﹤0.01% 2856
2021
Q3 		$250K Buy
+844
New +$253K ﹤0.01% 2839

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

RhumbLine Advisers's LYEL Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Lyell Immunopharma (LYEL) in Q2 2026: 15,462 shares worth $217K. The stake represents ﹤0.01% of the portfolio and ranks #3242 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in LYEL as recently as Q1 2025.

RhumbLine Advisers first reported a position in LYEL in Q3 2021 and has held it in 16 quarters since. The position peaked at $1.96M in Q3 2022. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • RhumbLine Advisers held 15,462 shares of Lyell Immunopharma worth $217K as of Q2 2026.
  • Lyell Immunopharma was a new RhumbLine Advisers position in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3242 holding.
  • RhumbLine Advisers first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 16 quarters since.
  • RhumbLine Advisers's Lyell Immunopharma position peaked at $1.96M in Q3 2022.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.